Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

A comparison between 52 patients with CLL and 52 sex- and aged-matched healthy controls after administration of the second dose, noted a significantly reduced antibody response rate among CLL patients (52% vs 100%, respectively; adjusted OR 0.010, 95% CI 0.001-0.162; p<0.001).

Source:

Blood